Regeneron, Sanofi: Dupixent Hits Endpoints in Atopic Dermatitis Under Age 6
30 August 2021 - 9:07PM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and Sanofi SA on Monday said a
Phase 3 study of their blockbuster eczema drug Dupixent to treat
moderate-to-severe atopic dermatitis in children ages 6 months to 5
years met its primary and all secondary endpoints.
The companies said Dupixent added to standard-of-care topical
corticosteroids significantly reduced overall disease severity and
improved skin clearance, itch and health-related quality of life
measures at 16 weeks compared to topical corticosteroids alone.
Regeneron and Sanofi said Dupixent, which is already approved
for patients 6 years and older with uncontrolled moderate-to-severe
atopic dermatitis, is the first biologic medicine to show positive
results in the inflammatory skin disease in the study's young
population.
Regeneron, of Tarrytown, N.Y., created Dupixent and markets it
jointly in the U.S. with France's Sanofi under a 2007 collaboration
agreement. Sanofi markets the product internationally.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 30, 2021 06:52 ET (10:52 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2024 to May 2024
Sanofi (EU:SAN)
Historical Stock Chart
From May 2023 to May 2024